---
type: "Topics"
locale: "en"
url: "https://longbridge.com/en/topics/100000000545200.md"
description: "$Hims & Hers Health(HIMS.US) holds leading scale in US direct-to-consumer personalized telehealth (~2x the size of many #2 players).Core moat includes data flywheel (labs with 130+ biomarkers), high customer trust/brand, low churn via subscriptions, and supplier networks. Competitors include Ro/Roman, traditional telehealth, and branded pharma direct channels.Threats from GLP-1 price competition and compounding regulations are being actively mitigated via branded pivots and diversification. Market share continues expanding in core categories.@Bridge Buzz SG"
datetime: "2026-03-24T04:07:05.000Z"
locales:
  - [en](https://longbridge.com/en/topics/100000000545200.md)
  - [zh-CN](https://longbridge.com/zh-CN/topics/100000000545200.md)
  - [zh-HK](https://longbridge.com/zh-HK/topics/100000000545200.md)
author: "[Marina Bay](https://longbridge.com/en/profiles/26381638.md)"
generator: "portal-rs"
---

# $Hims & Hers Health(HIMS.US) holds leading sca…


### Related Stocks

- [HIMS.US](https://longbridge.com/en/quote/HIMS.US.md)
- [GLP.US](https://longbridge.com/en/quote/GLP.US.md)
- [GLP-B.US](https://longbridge.com/en/quote/GLP-B.US.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**